Deepu Madduri, MD

Articles by Deepu Madduri, MD

Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year

January 22nd 2021

The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.

Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma

ByDeepu Madduri, MD

January 20th 2021

The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.

Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial

ByDeepu Madduri, MD

January 18th 2021

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results

ByDeepu Madduri, MD

January 14th 2021

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

ByDeepu Madduri, MD

January 12th 2021

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Results of the Phase 1b/2 CARTITUDE-1 Trial

ByDeepu Madduri, MD

January 11th 2021

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.